FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588974447> ?p ?o ?g. }

• W2588974447 abstract "Abstract Introduction: Oprozomib (OPZ) is an irreversible, orally administered proteasome inhibitor (PI).It decreases tumor burden and prevents tumor-related bone loss in preclinical multiple myeloma (MM) studies. In recently published clinical trials, the combination of the PI carfilzomib with the immunomodulatory agent (IMiD) lenalidomide and dexamethasone (Dex) has shown high response rates with durable responses for previously treated and untreated MM patients. Carfilzomib with the IMiD pomalidomide (Pom) and Dex for the treatment of RRMM patients shows promising results (Shah et al, 2013). We evaluated OPZ in combination with Pom and Dex using two of our human MM xenograft models in severe combined immunodeficient (SCID) mice. Methods: Each SCID mouse (n=10/group) was surgically implanted with a 20 - 40 mm3 MM tumor piece into the hind limb. Seven days post-implantation mice were randomized into treatment groups based on human immunoglobulin (Ig) G levels. OPZ stock solution (4 mg/ml) was diluted to 40 mg/kg using 1% carboxymethylcellulose (CMC) and administered twice weekly on two consecutive days via oral gavage.Dex stock solution (10 mg/ml) was diluted to 1 mg/kg using NaCl and administered daily via intraperitoneal injection.Pom stock solution (1 mg/ml) was diluted to 10 mg/kg using 1% CMC and administered daily via oral gavage. Tumor size was measured using calipers and IgG levels by ELISA. Results: Using our human MM model LAGk-1A, treatment with single agent OPZ or Pom produced a minimal reduction in tumor volume when compared with vehicle-treated mice, whereas Dex alone or OPZ + Pom produced more anti-MM effects, and no differences were observed between these two groups. Mice treated with OPZ + Dex or Pom + Dex also showed greater anti-MM activity than OPZ + Pom or Dex alone but the differences were not significant. All three agents together resulted in much smaller tumors when compared to OPZ + Pom on days 35, 42, 49 and 56 (P = 0.0006, P = 0.0001, P = 0.0002 and P < 0.0001, respectively). The same triplicate resulted in a smaller tumors when compared to OPZ + Dex on days 35, 42, 49, 56, and 63 (P = 0.0112, P = 0.0030, P = 0.0060, P = 0.0035 and P = 0.0021, respectively). Although Pom + Dex had some anti-MM effects when compared to the three single agents and one of the doublets (OPZ + Pom), mice receiving the triplicate demonstrated markedly smaller tumors when compared with Pom + Dex on days 35, 42, 49, 56, 63, 70, and 77 (P = 0.0250, P = 0.0018, P < 0.0001, P = 0.0014, P = 0.0018, P = 0.0017 and P = 0.0014, respectively). Mice receiving Pom + Dex had to be euthanized on day 77, whereas mice receiving all three drugs had very small tumors at study termination. We obtained similar results in a second MM xenograft model that produces IgG (LAGλ-1). Although day 21 post-tumor implantation mice receiving Pom alone had lower IgG levels compared with vehicle-treated mice (P = 0.0053), mice receiving OPZ + Pom had smaller tumors when compared to Pom alone (P = 0.0387), OPZ alone (P = 0.0004), or vehicle-treated mice (P = 0.0001). Although mice receiving Pom alone had a reduction in tumor size when compared with vehicle-treated mice (P = 0.0021), mice receiving OPZ + Pom had smaller tumors when compared with Pom alone (P = 0.0081), OPZ alone (P = 0.0007), or vehicle-treated mice (P < 0.0001). Mice receiving the triplicate showed smaller tumors on day 28 compared with mice treated with either the doublets of Pom + Dex (P = 0.0120) or OPZ + Pom (P = 0.0043). Conclusions: These in vivo human MM xenograft studies show that the combination of OPZ + Pom + Dex shows greater anti-MM activity than doublets (Pom + Dex, OPZ + Dex or OPZ + Pom) or single agents, and provides further support for this three drug combination to treat MM. Disclosures Tang: Onyx: Research Funding. Berenson@imbcr.org:Onyx: Consultancy, Honoraria, Research Funding, Speakers Bureau." @default.
• W2588974447 created "2017-02-24" @default.
• W2588974447 creator A5005405176 @default.
• W2588974447 creator A5038431825 @default.
• W2588974447 creator A5041743845 @default.
• W2588974447 creator A5046398383 @default.
• W2588974447 creator A5061288330 @default.
• W2588974447 creator A5070323205 @default.
• W2588974447 creator A5075681372 @default.
• W2588974447 creator A5085360438 @default.
• W2588974447 creator A5090300095 @default.
• W2588974447 date "2015-12-03" @default.
• W2588974447 modified "2023-09-27" @default.
• W2588974447 title "Effects of Oprozomib in Combination with Pomalidomide and/or Dexamethasone on Human Multiple Myeloma Tumors Growing in SCID Mice" @default.
• W2588974447 doi "https://doi.org/10.1182/blood.v126.23.5349.5349" @default.
• W2588974447 hasPublicationYear "2015" @default.
• W2588974447 type Work @default.
• W2588974447 sameAs 2588974447 @default.
• W2588974447 citedByCount "1" @default.
• W2588974447 countsByYear W25889744472020 @default.
• W2588974447 crossrefType "journal-article" @default.
• W2588974447 hasAuthorship W2588974447A5005405176 @default.
• W2588974447 hasAuthorship W2588974447A5038431825 @default.
• W2588974447 hasAuthorship W2588974447A5041743845 @default.
• W2588974447 hasAuthorship W2588974447A5046398383 @default.
• W2588974447 hasAuthorship W2588974447A5061288330 @default.
• W2588974447 hasAuthorship W2588974447A5070323205 @default.
• W2588974447 hasAuthorship W2588974447A5075681372 @default.
• W2588974447 hasAuthorship W2588974447A5085360438 @default.
• W2588974447 hasAuthorship W2588974447A5090300095 @default.
• W2588974447 hasConcept C126322002 @default.
• W2588974447 hasConcept C126894567 @default.
• W2588974447 hasConcept C2776063141 @default.
• W2588974447 hasConcept C2776364478 @default.
• W2588974447 hasConcept C2778524551 @default.
• W2588974447 hasConcept C2780108899 @default.
• W2588974447 hasConcept C2780401358 @default.
• W2588974447 hasConcept C71924100 @default.
• W2588974447 hasConcept C98274493 @default.
• W2588974447 hasConceptScore W2588974447C126322002 @default.
• W2588974447 hasConceptScore W2588974447C126894567 @default.
• W2588974447 hasConceptScore W2588974447C2776063141 @default.
• W2588974447 hasConceptScore W2588974447C2776364478 @default.
• W2588974447 hasConceptScore W2588974447C2778524551 @default.
• W2588974447 hasConceptScore W2588974447C2780108899 @default.
• W2588974447 hasConceptScore W2588974447C2780401358 @default.
• W2588974447 hasConceptScore W2588974447C71924100 @default.
• W2588974447 hasConceptScore W2588974447C98274493 @default.
• W2588974447 hasLocation W25889744471 @default.
• W2588974447 hasOpenAccess W2588974447 @default.
• W2588974447 hasPrimaryLocation W25889744471 @default.
• W2588974447 hasRelatedWork W1443108546 @default.
• W2588974447 hasRelatedWork W2184894809 @default.
• W2588974447 hasRelatedWork W2324786078 @default.
• W2588974447 hasRelatedWork W2345512270 @default.
• W2588974447 hasRelatedWork W2365633901 @default.
• W2588974447 hasRelatedWork W2369764254 @default.
• W2588974447 hasRelatedWork W2370642444 @default.
• W2588974447 hasRelatedWork W2378628095 @default.
• W2588974447 hasRelatedWork W2380807696 @default.
• W2588974447 hasRelatedWork W2388762021 @default.
• W2588974447 hasRelatedWork W2550365187 @default.
• W2588974447 hasRelatedWork W2552672983 @default.
• W2588974447 hasRelatedWork W2557733183 @default.
• W2588974447 hasRelatedWork W2558296050 @default.
• W2588974447 hasRelatedWork W2572796572 @default.
• W2588974447 hasRelatedWork W2582838532 @default.
• W2588974447 hasRelatedWork W2586835967 @default.
• W2588974447 hasRelatedWork W2588538618 @default.
• W2588974447 hasRelatedWork W2784043644 @default.
• W2588974447 hasRelatedWork W2978553166 @default.
• W2588974447 isParatext "false" @default.
• W2588974447 isRetracted "false" @default.
• W2588974447 magId "2588974447" @default.
• W2588974447 workType "article" @default.